ReviewCancers2022
Strategies for Radioiodine Treatment: What's New.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.Endocrine journal · 2025Guideline
- Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.Endocrine · 2024Pooled it
- Targeted tumor starvation strategy augments radiosensitivity and enhances radioactive iodine-mediated tumor immunotherapy.Acta pharmacologica Sinica · 2026Article
- Low-iodine diet: what to eat and avoid before iodine-131 procedures?Annals of nuclear medicine · 2025Review
- Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.International journal of molecular sciences · 2025Review
- The Current Understanding of the Molecular Pathogenesis of Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- The Impact of Radioactive Iodine on Outcomes Among Pediatric and Adolescent Thyroid Cancer Patients: A SEER Database Analysis.Cancers · 2025Article
- Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [Current radiopharmaceuticals · 2025Article
- Use and utility of endocrine multidisciplinary tumour board: an appraisal from a tertiary centre.Frontiers in endocrinology · 2025Article
- Role of Radioiodine in Cancer Therapy: A Review of the Design and Challenges in Selecting Radioligands from Natural Sources.Drug design, development and therapy · 2025Review
- Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics.The Journal of clinical endocrinology and metabolism · 2024Article
- Advances in the Diagnosis and Treatment of Follicular Thyroid Carcinoma: A Comprehensive Review.Cureus · 2024Review
- [Female reproductive function after radioiodine therapy for differentiated thyroid carcinoma].Problemy endokrinologii · 2024Review
- Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer.Journal of inflammation research · 2024Article
- Article
- CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.International journal of molecular sciences · 2023Review
- Effects of apitherapy against salivary gland disorder after radioactive iodine therapy for differentiated thyroid cancer.Annals of nuclear medicine · 2023Article
- BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category.International journal of molecular sciences · 2023Article
- The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients.Cancers · 2023Article
- Proteomic analysis of radioiodine-refractory differentiated thyroid cancer identifies CHI3L1 upregulation in association with dysfunction of the sodium-iodine symporter.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioiodine treatment (RAI) represents the most widespread and effective therapy for differentiated thyroid cancer (DTC). RAI goals encompass ablative (destruction of thyroid remnants, to enhance thyroglobulin predictive value), adjuvant (destruction of microscopic disease to reduce recurrences), and therapeutic (in case of macroscopic iodine avid lesions) purposes, but its use has evolved over time. Randomized trial results have enabled the refinement of RAI indications, moving from a standardized practice to a tailored approach. In most cases, low-risk patients may safely avoid RAI, but where necessary, a simplified protocol, based on lower iodine activities and human recombinant TSH preparation, proved to be just as effective, reducing overtreatment or useless impairment of quality of life. In pediatric DTC, RAI treatments may allow tumor healing even at the advanced stages. Finally, new challenges have arisen with the advancement in redifferentiation protocols, through which RAI still represents a leading therapy, even in former iodine refractory cases. RAI therapy is usually well-tolerated at low activities rates, but some concerns exist concerning higher cumulative doses and long-term outcomes. Despite these achievements, several issues still need to be addressed in terms of RAI indications and protocols, heading toward the RAI strategy of the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.